Centaur Labs vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 34)
Centaur Labs logo

Centaur Labs

NicheHealthcare

Medical AI Training Data Annotation via Collective Intelligence

Centaur Labs is a medical data annotation company that uses collective intelligence — aggregating input from a crowd of vetted medical professionals — to produce high-accuracy training labels for medical AI models;

AI VisibilityBeta
Overall Score
D34
Category Rank
#585 of 596
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
29
Perplexity
38
Gemini
31

About

Centaur Labs is a medical data annotation company headquartered in Boston, Massachusetts, founded in 2018 by Erik Duhaime and others. The company has built a platform that produces high-accuracy medical AI training data by aggregating annotations from a curated crowd of medical professionals — physicians, nurses, medical students, and other clinicians — rather than relying on individual expert annotation or general-purpose crowdsourcing. Its core insight is that combining many clinician judgments on ambiguous medical cases produces annotations that are as accurate as (or more accurate than) single expert opinions, while being dramatically faster and more scalable.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

34
Overall Score
93
#585
Category Rank
#1
76
AI Consensus
80
stable
Trend
up
29
ChatGPT
94
38
Perplexity
89
31
Gemini
94
30
Claude
92
36
Grok
98

Key Details

Category
Medical AI Training Data Annotation via Collective Intelligence
Enterprise
Tier
Niche
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.